Amgen Inc
amgen.comWhat Do They Do?
Develops, manufactures and sells medicines for serious diseases to healthcare providers and patients.
10-K for FY2025, filed Feb 13, 2026Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and…View ↗
The largest concentration of our sales and marketing forces is based in the United States and Europe. We also commercialize and market our…View ↗
In the United States, substantially all of our sales are to pharmaceutical wholesale distributors, which is the principal means of…View ↗
How Do They Make Money?
Product sales bring in money when Amgen delivers medicines to customers; payment is generally due after shipment. Other revenue mainly comes from royalties tied to licensees' product sales and collaboration fees, milestones and profit sharing.
10-K for FY2025, filed Feb 13, 2026Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount…View ↗
Our payment terms vary by types and locations of customers and by products or services offered. Payment terms differ by jurisdiction and…View ↗
Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales…View ↗
From time to time, we enter into arrangements for the R&D, manufacture and/or commercialization of products and product candidates. Such…View ↗
$36.8B
-
10-K for FY2025, filed Feb 13, 2026
$36.8B ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales
Sold outright
10-K for FY2025, filed Feb 13, 2026 |
96%
FY2022: 94%
|
Product sales, FY2025
$35.1B Sources
|
Sold outright |
|
Other revenues
Mix
|
4.4%
FY2022: 5.8%
|
Other revenues, FY2025
$1.6B Sources
|
Mix |
Who Are Their Customers?
In the United States, Amgen sells mainly to wholesalers, which distribute medicines to healthcare providers; elsewhere, it sells mainly to providers or wholesalers. It also markets products through collaborators in some countries and certain products through direct-to-patient channels.
10-K for FY2025, filed Feb 13, 2026The largest concentration of our sales and marketing forces is based in the United States and Europe. We also commercialize and market our…View ↗
In the United States, substantially all of our sales are to pharmaceutical wholesale distributors, which is the principal means of…View ↗
In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our…View ↗
10-K for FY2025, filed Feb 13, 2026
Years ended December 31, 2025 2024 2023 McKesson Corporation: Gross product sales $ 26,253 $ 22,173 $ 19,035 % of total gross revenues 34 %…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 21 cents of every revenue dollar as net income in FY2025 and turned 22 cents into free cash flow.
10-K for FY2025, filed Feb 13, 2026
$9.1BView ↗
10-K for FY2025, filed Feb 13, 2026
$7.7BView ↗
10-K for FY2025, filed Feb 13, 2026
$8.1BView ↗
How Are They Changing?
10-Q for Q2 FY2026, filed Aug 5, 2026
Open tableView ↗
-
May 19, 2026
CFO Peter Griffith is retiring; Thomas Dittrich will succeed him
Griffith's CFO retirement is effective August 31, 2026, and Dittrich takes over September 1, 2026.
Sources
8-K, filed May 19, 2026
On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griffith will retire from the role of the Company’s Executive…View ↗
Growing. Revenue grew 41% in 4 years, from $26B in FY2021 to $36.8B in FY2025, about 9% a year.
Who Do They Compete With?
Competes with Regeneron Pharmaceuticals, Sanofi, Eli Lilly and, Bristol Myers Squibb, Pfizer, Asahi Kasei Pharma, AstraZeneca, GSK, Genentech, Celgene, Takeda Pharmaceutical, Legend Biotech, Roche, Merck KGaA, and Merck &
10-K for FY2025, filed Feb 13, 2026Regeneron Pharmaceuticals, Inc.View ↗
Loading...
